ZFuze is an anti-inflammatory, osseoconductive, load-bearing biomaterial, according to a Jan. 14 news release. It’s the first biomaterial of its kind approved by the FDA, and ZFuze has a 93.4% lumbar spinal fusion rate at six months.
The patent protects ZFuze’s Master File for another 17 years, CEO and founder Derrick Johns said in the release.
